A Fortune 500 pharmaceutical company aimed to improve patient outcomes by understanding and enhancing medication adherence. They needed to identify patients at risk of therapy discontinuation within six months and understand the key factors at play. The challenges were multifaceted, involving evolving business rules, data capture processes, and integration of complex data, including intangible factors like patient perception and disease awareness.
The client, with our expertise, processed data from diverse sources and successfully predicted therapy discontinuation, allowing them to design targeted care plans. They analyzed a sample size of 7,000 patients across two therapeutic areas and gained insights into the root causes of therapy discontinuation.